drugset / Trial / NCT00608335

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335

Phase 1 Completed 84 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelOther

Summary

Children with fungal infections will be divided into two groups by weight. Children weighing \< 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing \> 25 kg.

Timeline

Start
2007-10-14
Primary completion
2011-09-08
Completion
2011-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide 3 mg/kg
Subject Micafungin Peptide 4.5 mg/kg